Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.

Although the results of bradycardia and atrioventricular block in that study did not reach statistical significance compared to this study, mainly due to the relatively small number of cases, the RRs that study tended to differ between the fingolimod and control treatment groups, which is broadly consistent with our findings.

also in 111,027 other papers